Limits...
In Vivo and Impression Cytology Study on the Effect of Compatible Solutes Eye Drops on the Ocular Surface Epithelial Cell Quality in Dry Eye Patients.

Lanzini M, Curcio C, Colabelli-Gisoldi RA, Mastropasqua A, Calienno R, Agnifili L, Nubile M, Mastropasqua L - Mediators Inflamm. (2015)

Bottom Line: No significant difference in Schirmer I Test, TBUT, and vital staining results was observed during the follow-up period in both groups.A significant reduction of the expression of MMP9 and IL6 in Optive group was observed during the follow-up period in comparison to Hylogel treatment.Our results show that in dry eye disease therapy based on osmoprotective eye drops determines a reduction of inflammatory activation of ocular surface, with consequent improvement of the quality of corneal and conjunctival epithelium.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine and Ageing Sciences, Ophthalmology Clinic, University "G. d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.

ABSTRACT
The aim of this study is to investigate in vivo and ex vivo ocular surface alterations induced by dry eye disease and modification after osmoprotective therapy. Forty-eight eyes of 24 patients suffering from dry eye have been recruited. All patients received Optive (compatible solutes) eye drops in one randomly selected eye and Hylogel (sodium hyaluronate 0,2%) in the other. Follow-up included a baseline visit and further examination 30-, 60-, and 90-day intervals (which comprises clinical evaluation, in vivo confocal microscopy-IVCM-of the ocular surface, and conjunctival impression cytology). No significant difference in Schirmer I Test, TBUT, and vital staining results was observed during the follow-up period in both groups. IVCM showed in all patients an improvement of ocular surface epithelial morphology and signs of inflammation (oedema and keratocyte activation). However, these modifications were more evident in patients treated with Optive therapy. A significant reduction of the expression of MMP9 and IL6 in Optive group was observed during the follow-up period in comparison to Hylogel treatment. Our results show that in dry eye disease therapy based on osmoprotective eye drops determines a reduction of inflammatory activation of ocular surface, with consequent improvement of the quality of corneal and conjunctival epithelium.

No MeSH data available.


Related in: MedlinePlus

IVCM images of ocular surface in dry eye. (a) Squamous metaplasia of conjunctival epithelium. (b) Irregularity and desquamation of conjunctival epithelium. (c–f) Improving of quality and regularity of conjunctival epithelial cells more evident after 90 days of Optive treatment (c-d) with respect to Hylogel group (e-f).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4499618&req=5

fig1: IVCM images of ocular surface in dry eye. (a) Squamous metaplasia of conjunctival epithelium. (b) Irregularity and desquamation of conjunctival epithelium. (c–f) Improving of quality and regularity of conjunctival epithelial cells more evident after 90 days of Optive treatment (c-d) with respect to Hylogel group (e-f).

Mentions: In both groups, the morphology of corneal and conjunctival epithelia showed an improvement during the follow-up period. Comparing baseline images with findings at 30, 60, and 90 days after treatment, a decrease in reflectivity of superficial cells was observed together with an increase of regularity of cell shape and size. No morphological differences were revealed between the two groups (Figure 1).


In Vivo and Impression Cytology Study on the Effect of Compatible Solutes Eye Drops on the Ocular Surface Epithelial Cell Quality in Dry Eye Patients.

Lanzini M, Curcio C, Colabelli-Gisoldi RA, Mastropasqua A, Calienno R, Agnifili L, Nubile M, Mastropasqua L - Mediators Inflamm. (2015)

IVCM images of ocular surface in dry eye. (a) Squamous metaplasia of conjunctival epithelium. (b) Irregularity and desquamation of conjunctival epithelium. (c–f) Improving of quality and regularity of conjunctival epithelial cells more evident after 90 days of Optive treatment (c-d) with respect to Hylogel group (e-f).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4499618&req=5

fig1: IVCM images of ocular surface in dry eye. (a) Squamous metaplasia of conjunctival epithelium. (b) Irregularity and desquamation of conjunctival epithelium. (c–f) Improving of quality and regularity of conjunctival epithelial cells more evident after 90 days of Optive treatment (c-d) with respect to Hylogel group (e-f).
Mentions: In both groups, the morphology of corneal and conjunctival epithelia showed an improvement during the follow-up period. Comparing baseline images with findings at 30, 60, and 90 days after treatment, a decrease in reflectivity of superficial cells was observed together with an increase of regularity of cell shape and size. No morphological differences were revealed between the two groups (Figure 1).

Bottom Line: No significant difference in Schirmer I Test, TBUT, and vital staining results was observed during the follow-up period in both groups.A significant reduction of the expression of MMP9 and IL6 in Optive group was observed during the follow-up period in comparison to Hylogel treatment.Our results show that in dry eye disease therapy based on osmoprotective eye drops determines a reduction of inflammatory activation of ocular surface, with consequent improvement of the quality of corneal and conjunctival epithelium.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine and Ageing Sciences, Ophthalmology Clinic, University "G. d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.

ABSTRACT
The aim of this study is to investigate in vivo and ex vivo ocular surface alterations induced by dry eye disease and modification after osmoprotective therapy. Forty-eight eyes of 24 patients suffering from dry eye have been recruited. All patients received Optive (compatible solutes) eye drops in one randomly selected eye and Hylogel (sodium hyaluronate 0,2%) in the other. Follow-up included a baseline visit and further examination 30-, 60-, and 90-day intervals (which comprises clinical evaluation, in vivo confocal microscopy-IVCM-of the ocular surface, and conjunctival impression cytology). No significant difference in Schirmer I Test, TBUT, and vital staining results was observed during the follow-up period in both groups. IVCM showed in all patients an improvement of ocular surface epithelial morphology and signs of inflammation (oedema and keratocyte activation). However, these modifications were more evident in patients treated with Optive therapy. A significant reduction of the expression of MMP9 and IL6 in Optive group was observed during the follow-up period in comparison to Hylogel treatment. Our results show that in dry eye disease therapy based on osmoprotective eye drops determines a reduction of inflammatory activation of ocular surface, with consequent improvement of the quality of corneal and conjunctival epithelium.

No MeSH data available.


Related in: MedlinePlus